| Conjoint analysis applications in health—a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force JFP Bridges, AB Hauber, D Marshall, A Lloyd, LA Prosser, DA Regier, ... Value in health 14 (4), 403-413, 2011 | 1904 | 2011 |
| Constructing experimental designs for discrete-choice experiments: report of the ISPOR conjoint analysis experimental design good research practices task force FR Johnson, E Lancsar, D Marshall, V Kilambi, A Mühlbacher, DA Regier, ... Value in health 16 (1), 3-13, 2013 | 1785 | 2013 |
| Evaluating health-related quality-of-life studies in paediatric populations: some conceptual, methodological and developmental considerations and recent applications M De Civita, D Regier, AH Alamgir, AH Anis, MJ FitzGerald, CA Marra Pharmacoeconomics 23, 659-685, 2005 | 349 | 2005 |
| Handbook of statistics in clinical oncology J Crowley CRC Press, 2012 | 259 | 2012 |
| Pan-cancer analysis of advanced patient tumors reveals interactions between therapy and genomic landscapes E Pleasance, E Titmuss, L Williamson, H Kwan, L Culibrk, EY Zhao, ... Nature Cancer 1 (4), 452-468, 2020 | 147 | 2020 |
| Multi-criteria decision analysis to support healthcare decisions K Marsh, M Goetghebeur, P Thokala, R Baltussen Springer 10, 978-3, 2017 | 130 | 2017 |
| Cost-effectiveness of self-managed versus physician-managed oral anticoagulation therapy DA Regier, R Sunderji, LD Lynd, K Gin, CA Marra CMAJ 174 (13), 1847-1852, 2006 | 113 | 2006 |
| Chemotherapy versus supportive care alone in pediatric palliative care for cancer: comparing the preferences of parents and health care professionals D Tomlinson, U Bartels, J Gammon, PS Hinds, J Volpe, E Bouffet, ... Cmaj 183 (17), E1252-E1258, 2011 | 109 | 2011 |
| Societal preferences for the return of incidental findings from clinical genomic sequencing: a discrete-choice experiment DA Regier, SJ Peacock, R Pataky, K van der Hoek, GP Jarvik, J Hoch, ... Cmaj 187 (6), E190-E197, 2015 | 103 | 2015 |
| Bayesian and classical estimation of mixed logit: an application to genetic testing DA Regier, M Ryan, E Phimister, CA Marra Journal of health economics 28 (3), 598-610, 2009 | 100 | 2009 |
| An overview of economic evaluations for drugs used in rheumatoid arthritis: Focus on tumour necrosis factor-α antagonists NJ Bansback, DA Regier, R Ara, A Brennan, K Shojania, JM Esdaile, ... Drugs 65, 473-496, 2005 | 96 | 2005 |
| Return of incidental findings in genomic medicine: measuring what patients value—development of an instrument to measure preferences for information from next-generation … CS Bennette, SB Trinidad, SM Fullerton, D Patrick, L Amendola, W Burke, ... Genetics in Medicine 15 (11), 873-881, 2013 | 89 | 2013 |
| Whole-genome and transcriptome analysis enhances precision cancer treatment options E Pleasance, A Bohm, LM Williamson, JMT Nelson, Y Shen, M Bonakdar, ... Annals of oncology 33 (9), 939-949, 2022 | 86 | 2022 |
| Clarifying values: an updated and expanded systematic review and meta-analysis HO Witteman, R Ndjaboue, G Vaisson, SC Dansokho, B Arnold, ... Medical Decision Making 41 (7), 801-820, 2021 | 86 | 2021 |
| Value for money? Array genomic hybridization for diagnostic testing for genetic causes of intellectual disability DA Regier, JM Friedman, CA Marra The American Journal of Human Genetics 86 (5), 765-772, 2010 | 83 | 2010 |
| Methodological issues in assessing the economic value of next-generation sequencing tests: many challenges and not enough solutions KA Phillips, PA Deverka, DA Marshall, S Wordsworth, DA Regier, ... Value in Health 21 (9), 1033-1042, 2018 | 74 | 2018 |
| Valuation of health and nonhealth outcomes from next-generation sequencing: approaches, challenges, and solutions DA Regier, D Weymann, J Buchanan, DA Marshall, S Wordsworth Value in Health 21 (9), 1043-1047, 2018 | 70 | 2018 |
| The cost and cost trajectory of whole‐genome analysis guiding treatment of patients with advanced cancers D Weymann, J Laskin, R Roscoe, KA Schrader, S Chia, S Yip, ... Molecular genetics & genomic medicine 5 (3), 251-260, 2017 | 68 | 2017 |
| Valuing the benefit of diagnostic testing for genetic causes of idiopathic developmental disability: willingness to pay from families of affected children DA Regier, JM Friedman, N Makela, M Ryan, CA Marra Clinical genetics 75 (6), 514-521, 2009 | 68 | 2009 |
| Addressing challenges of economic evaluation in precision medicine using dynamic simulation modeling DA Marshall, LR Grazziotin, DA Regier, S Wordsworth, J Buchanan, ... Value in health 23 (5), 566-573, 2020 | 59 | 2020 |